Compare Moderna, Inc. (MRNA) vs United Airlines Holdings Inc (UAL) Price & Performance

Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.

The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.

United Airlines (UAL) trades at $108.24, down 2.82% today, with a bearish technical signal but strong fundamentals including a P/E of 10.13 and net income margin of 5.56%. The company has beaten EPS estimates for three consecutive quarters and announced its largest international expansion, adding 10 new routes for 2027. Cash flow trends show volatility, with 2025 net cash flow negative at -$2.86 billion but projected to turn positive in 2026.

The outlook is mixed: analyst consensus is strongly bullish with a $168.96 price target, but high jet fuel costs and geopolitical risks pose headwinds. Earnings growth and international expansion are key catalysts, while debt levels and operational efficiency remain areas to watch for sustained shareholder value.